Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report

José Ramón Santos 1,2*, Ana Merino 3,4, Walter E. Haefeli 5, Cristina Miranda 1, Marisol Prats 6, Ioana Bancu 3,4, Lucía Bailón 1 and José Moltó 1,2

Abstract

Background: Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD).

Case presentation: A 53-year-old woman with HIV/hepatitis C virus (HCV) co-infection, PAH and ESRD on regular hemodialysis was admitted in our hospital due to refractory heart failure while on treatment with bosentan (125 mg twice daily) and tadalafil (20 mg once daily) for PAH and antiretroviral treatment (cART) including darunavir/cobicistat (800/150 mg once daily). Excessive exposure to bosentan due to drug interactions between bosentan and darunavir/cobicistat was suspected. Bosentan was replaced by ambrisentan, with progressive improvement in her clinical condition. Pre- and postdialyzer concentrations of ambrisentan in plasma were determined and hemodialysis extraction ratio for ambrisentan was 2%.

Conclusions: Our results suggest that hemodialysis results in minimal ambrisentan removal, and therefore no specific ambrisentan dosage adjustment seems to be required in ESRD patients undergoing hemodialysis.

Keywords: Ambrisentan, Hemodialysis, Pulmonary arterial hypertension, HIV-infection, Drug interactions

Background

The life expectancy of people living with HIV has shown significant improvement in recent decades, largely due to the widespread use of combined antiretroviral therapy (cART). However, this has been followed by an increase in the prevalence of non-AIDS-defining co-morbidities, including pulmonary arterial hypertension (PAH) and chronic kidney disease [1, 2]. The prevalence of PAH in the HIV population is approximately 0.5%, with a little variation since the introduction of cART. Nevertheless, the number of HIV-infected patients with end-stage renal disease (ESRD) requiring renal replacement therapy has increased.

Defining optimal dosing of many drugs in patients on hemodialysis may be difficult. Drug removal by hemodialysis is an essential factor in determining different dosing regimens. However, the pharmacokinetics of many drugs in patients on hemodialysis has been poorly studied, and information about their hemodialyzability remains scant [3–5]. In addition, HIV patients with PAH or ESRD are frequently affected by other co-morbidities that require specific therapies. These patients often receive many different drugs (polypharmacy), with a potential risk for drug-drug interactions among them [6, 7]. Here we report a clinical case involving an HIV-1-infected patient with severe PAH and ESRD on hemodialysis who was treated with ambrisentan with the intention to avoid drug interactions between bosentan and cART. Ambrisentan is a selective endothelin-A receptor antagonist, which is approved for the treatment of pulmonary arterial hypertension (PAH) in patients with WHO functional class III or IV PAH.
of PAH [8, 9]. However, despite its better pharmacokinetic profile in comparison to bosentan, no data on ambrisentan pharmacokinetics in hemodialysis patients were available, so we evaluated the effect of hemodialysis on ambrisentan concentrations.

Case presentation
The patient in this clinical case was a 53-year-old woman who was admitted to our hospital with severe respiratory failure. She had been diagnosed with HIV/hepatitis C virus (HCV) co-infection in 2000 as well as with PAH in 2002. In addition, she had ESRD and had been undergoing high-flux hemodialysis sessions since 2014 (vascular access: venous-arterial fistula; dialyzer: Revaclear® 400, capillary 101 dialyzer, membrane area 1.8 m²; Bicart® Gambro bicarbonate cartridge; blood flow: 350 mL/min; dialysate flow: 500 mL/min). The patient was undergoing 3 dialysis sessions per week and each session lasted approximately 4 h.

In January 2018, the patient was receiving cART with lopinavir/ritonavir (400/100 mg twice daily) plus raltegravir (400 mg twice daily), as well as bosentan (125 mg twice daily) plus tadalafil (20 mg once daily) for PAH. At that time, treatment with glecaprevir/pibrentasvir was indicated for HCV. To avoid drug interactions with HCV drugs, cART was switched to raltegravir (400 mg twice daily) plus rilpivirine (25 mg once daily), and bosentan and tadalafil were temporarily discontinued. In April 2018, after completing 8 weeks of HCV treatment, bosentan and tadalafil were reintroduced at the same doses as before HCV treatment, and rilpivirine was replaced by darunavir/ritonavir (800/150 mg once daily).

From April 2018 to September 2018 the patient had several episodes of congestive heart failure, which were satisfactory managed with medical treatment. Nevertheless, in September 2018 the patient presented with severe respiratory failure and clinical signs compatible with decompensated heart failure, and she had to be hospitalized. On her admission, the patient underwent daily hemodialysis sessions, and the negative fluid balance in each session was increased. However, the response to hemodialysis was poorer than expected, suggesting additional determinants of her clinical situation. In addition, during the admission, virologic failure was evidenced by an HIV-1 RNA load in plasma of 5424 copies/mL, with HIV evolution and development of new drug resistance mutations in the integrase gene (N155H) not present in previous genotypes. After ruling out other conditions, bosentan toxicity—probably because excessive exposure to bosentan due to drug interactions between bosentan and darunavir/ritonavir/cobicistat was considered. Bosentan was therefore replaced by ambrisentan with the intention of avoiding drug-drug interactions with cART. Additionally, cART was optimized, and the regimen was changed to darunavir/ritonavir (800/100 mg once daily) plus etravirine (200 mg twice daily) and dolutegravir (50 mg twice daily). Thereafter, the patient experienced progressive improvement in her clinical condition, HIV RNA in plasma was re-suppressed (< 40 copies/ml), and she was finally discharged to resume her usual hemodialysis program (3 sessions per week).

To evaluate the effect of hemodialysis on ambrisentan plasma concentrations, paired samples of blood entering (‘in’) and leaving (‘out’) the dialyzer and of the resulting dialysate were collected during one dialysis session. Blood samples were collected into heparin-lithium-containing 4-ml tubes 12.2 h after last ambrisentan dose. Plasma was isolated by centrifugation (3200 g for 15 min), and stored at − 80 °C until analysis. Dialysate (20 ml) was directly collected from the dialysate port of the dialyzer. Ambrisentan concentrations in both plasma and dialysate were determined using high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) using a validated method [10], and the hemodialysis extraction ratio (ER) for ambrisentan was calculated following standard procedures [5]. The patient gave and signed an informed consent before sampling took place.

The effect of hemodialysis on ambrisentan concentrations was evaluated during one hemodialysis session. Pre- and postdialyzer total ambrisentan concentrations were 42.8 ng/mL and 42.5 ng/mL, respectively, with negligible ambrisentan concentrations in dialysate (3.92 ng/mL). The hemodialysis extraction ratio was only 2.0%. At the end of the dialysis session (26.3 h after dosing), total ambrisentan concentrations in plasma were 35.6 ng/mL.

Discussion and conclusions
The small differences between plasma ambrisentan concentrations going in and coming out of the dialyzer, together with barely noticeable ambrisentan concentrations in dialysate in this patient, suggest a minimal removal of ambrisentan by hemodialysis in patients with ESRD. This finding is consistent with the physiochemical characteristics of ambrisentan, which is 99% bound to plasma proteins, and is minimally eliminated by the kidneys, with only 3% of its dose being excreted unchanged into urine [8].

Besides the effect of hemodialysis on ambrisentan concentrations, the clinical case presented here highlights the complexity of drug-drug interactions affecting HIV-infected patients. In this case, mutual interactions between bosentan and cART were suspected. The patient had clinical signs of fluid retention associated with bosentan toxicity, which was presumably the result of excessive bosentan concentrations due to potent cytochrome P450 3A4 (CYP3A4) inhibition by cobicistat. Although no specific studies have evaluated the effect of
cobicistat on bosentan pharmacokinetics, data with lopinavir/ritonavir have shown a rather substantial > 5-fold increase in bosentan exposure [11]. In the other direction, bosentan induces CYP3A4 activity [12], which is the main metabolic pathway for both darunavir and cobicistat. Previous studies have shown a decline in cobicistat exposure, and consequently inappropriately low darunavir concentrations, when darunavir/cobicistat is combined with the CYP3A4 inducers [13]. Consequently, combining bosentan with darunavir/cobicistat plus ritagra- vir could have resulted in functional monotherapy with raltegravir, leading to the virological failure and the development of new resistance mutations observed in this patient. Unfortunately, although it seems the most plausible hypothesis, no plasma samples to determine bosentan and antiretrovirals concentrations were available. Nevertheless, progressive improvement in the clinical condition of the pa- tient along with re-suppression of HIV RNA after switching to ambrisentan and ART adjustment is concordant with our theory.

Ambrisentan is a selective endothelin-A receptor antagonist with proven efficacy and safety in the treatment of PAH [8]. In contrast to bosentan, ambrisentan is only a minor sub- strate of CYP3A4 and its elimination is mainly mediated by glucuronidation via several uridine-glucuronosyltransferase (UGT) isozymes [8]. Thus, the effect of potent CYP3A4 in- hibitors on ambrisentan pharmacokinetics is much less com- pared to bosentan, and ambrisentan may be safely used in this scenario, as observed in our patient. Moreover, ambrisen- tan does not have any significant effect on the activity of UGT or cytochrome P450 isozymes or drug transporters, lim- iting the possibility of drug-drug interactions. It is noteworthy that ambrisentan concentrations at the end of the dialysis ses- sion were in the same range as those described in healthy vol- unteers receiving regular doses [14, 15], suggesting the absence of a need for dose adjustment in patients with ESRD.

Based on the minimal extraction ratio of ambrisentan by hemodialysis observed in our patient, no ambrisentan dose adjustment seems to be necessary in patients with PAH and ESRD undergoing hemodialysis. However, fur- ther investigations in this topic are recommendable. HIV-infected patients receiving polypharmacy may be affected by complex drug-drug interactions that require appropri- ate management, ideally by multidisciplinary teams with fluid communication among different prescribers.

Abbreviations
CART: Combined antiretroviral therapy; C_{out}: Predialyzer ambrisentan concentration; CYP3A4: Cytochrome P450 3A4; ER: Extraction ratio; ESRD: End-stage renal disease; HCV: Hepatitis C virus; LC-MS/MS: Liquid chromatography coupled with tandem mass spectrometry; PAH: Pulmonary arterial hypertension; TP: Total protein; UGT: Uridine-glucuronosyltransferase

Acknowledgements
We also wish to acknowledge the assistance of Michael Kennedy-Scanlon in proofreading the English in the final version of the manuscript.

Authors’ contributions
J.R.S., J.M., L.B. conceived and contributed to the study design; J.R.S, A.M., I.B., M.P., L.B. contributed to the patient inclusion and clinical management; J.M., W.E.H. contributed to evaluate ambrisentan plasma concentrations and to calculate the extraction ratio; C.M., A.M. contributed to sampling and data collection; J.R.S, A. M, W.E.H., M.P., I.B., L.B., J.M. contributed to the drafting of the manuscript and provided critical revisions of the manuscript. The authors had full access to the data, and the corresponding author had the final responsibility for submitting the manuscript for publication.

Funding
This work was supported by the Fundació Lluita contra la SIDA. The funder had no role in study design, data collection and analysis, interpretation of data, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not Applicable.

Consent for publication
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images and videos. A copy of the written consent is available for review by the Editor of this journal.

Competing of interests
W.E.H reports having received personal fees, non-financial support, or other support such as research grants from Actelion GmbH, Aspen Europe Gmbh, AstraZenica GmbH, BayerPharma AG, Berlin-Chemie AG, Boehringer GmbH, GSK, Bristol-Myers Squibb GmbH, Chiesi GmbH, Daiichi Sankyo GmbH, MSD, Sharp & Dohme GmbH, Roche, Grünenthal GmbH, Novartis, Pfizer GmbH, and personal fees and other from Roche GmbH, Smooth ClinicalTrials Ltd, Sumaya Biotec GmbH & Co. KG, and Vaximm GmbH. J.R. and J.M have re- ceived research funding, consultancy fees, and lecture sponsorships from and have served on advisory boards for various laboratories (MSD, Abbvie, Boehringer Ingelheim, Gilead Sciences, Viv Healthcare, Janssen Cilag, and Bristol-Myers-Squibb).

AM, CM, MF, LP, and IB have no conflicts of interest to declare.

Author details
1 Fundació Lluita contra la SIDA, Barcelona, Spain. 2 Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Ctra de Canyet, s/n, 08916 Badalona, Barcelona, Spain. 3 Universitat Autònoma de Barcelona, Barcelona, Spain. 4 Nephrology Department, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. 5 Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany. 6 Pulmonology Department, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.

Received: 1 August 2019 Accepted: 5 December 2019

References
1. Ando M, Yanagisawa N. Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients. World J Nephrol. 2015;4(3):388–95.
2. Nadkarni GN, Konstantinidis I, Wyatt CM. HIV and the aging kidney. Curr Opin HIV AIDS. 2014;9(4):340–5.
3. Urata M, Narita Y, Fukunaga M, et al. Simple formula for predicting drug removal rates during hemodialysis. Ther Apher Dial. 2018;22(5):485–93.
4. Hirata S, Izumi S, Furukubo T, et al. Factors influencing the removal rate of drugs by hemodialysis. J Jpn Soc Dial Ther. 2004;37:1893–900.
5. Motto J, Gräetzel F, Miranda C, et al. Removal of dolategravir by hemodialysis in HIV-infected patients with end-stage renal disease. Antimicrob Agents Chemother. 2016;60(4):2564–6.
6. Ware D, Pallela FJ Jr, Chew KW, et al. Prevalence and trends of polypharmacy among HIV-positive and negative men in the multicenter AIDS cohort study from 2004 to 2016. PLoS One. 2018;13(9):e0203890.
7. Núñez-Núñez M, Castañeda-Macías I, Sandoval-Fernández Del Castillo S. Potential interactions in a cohort of elderly hiv-positive patients. Farm Hosp. 2018;42(4):163–7.
8. Ambrisentan (Letairis) prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022081s033lbl.pdf.
9. Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int. 2013;84:682–92.
10. Enderle Y, Witt L, Wilkens H, et al. Simultaneous quantification of endothelin receptors antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary artery hypertension. J Pharm Biomed Anal. 2017;143:291–8.
11. Dingemanse J, van Gensbergen PL, Patat A, Nilsson PN. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir Ther. 2010;15(2):157–63.
12. Bosentan Tracleer prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf.
13. Moltó J, Currán A, Miranda C, et al. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients. J Antimicrob Chemother. 2018;73(3):732–7.
14. Markert C, Hellwig R, Burhenne J, et al. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. Eur J Clin Pharmacol. 2013;69(10):1785–93.
15. Markert C, Kastner IM, Hellwig R, et al. The effect of induction of CYP3A4 by St John’s wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype. Basic Clin Pharmacol Toxicol. 2015;116(5):423–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.